Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mtb72F/AS02 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Mtb72F/AS02A | BIOLOGICAL | - |
| Mtb72F/AS02. | BIOLOGICAL | - |
INCLUSION CRITERIA * Written informed consent * Healthy PPD-positive volunteers aged 18 to 50 years * No active pulmonary disease as confirmed by chest X-ray * No history of extrapulmonary TB * Seronegative for HIV 1 and 2, HBsAg, and HCV * Clinically normal laboratory values for creatinine, alanin...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT164a1, BNT164b1 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Ganfeborole |
Mtb72F/AS02 is an investigational vaccine candidate developed for the prevention of tuberculosis (TB). It was studied in healthy adult volunteers, including both PPD-negative and PPD-positive individuals, to evaluate its safety and immune response. It is not an approved product and remains in clinical development.
Mtb72F/AS02 is being developed by GSK plc, which trades under the ticker GSK. GSK Biologicals, the company's vaccine division, sponsored the clinical trials of this candidate tuberculosis vaccine.
Mtb72F/AS02 has been studied in Phase 1 and Phase 2 clinical trials. Both trials have been completed, and there are currently no active trials of this candidate. It is an investigational vaccine and has not been approved for any indication.
Mtb72F/AS02 has been evaluated in two completed clinical trials. NCT00291889 was a Phase 1 trial in 50 healthy PPD-negative adults in Belgium. NCT00146744 was a Phase 2 trial in 38 healthy PPD-positive adults in Switzerland. Both assessed safety and immunogenicity.